LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study

P.A. Ascierto, Mario Mandalà, Pier Francesco Ferrucci, Piotr Rutkowski, Massimo Guidoboni, A.M. Arance Fernandez, Virginia Ferraresi, Evaristo Maiello, Michele Guida, Michele Del Vecchio, Maria Teresa Fierro, Paola Queirolo, Célèste Lebbé, Hildur Helgadóttir, Ignacio Melero, Giuseppe Palmieri, Diana Giannarelli, Antonio Maria Grimaldi, Reinhard Dummer, V. Chiarion Sileni